Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median 3.4 years significantly reduced composite kidney endpoint (kidney failure, ≥50% eGFR decline, kidney death), slowed annual eGFR decline by 1.16 mL/min/1.73m², and reduced all-cause mortality by 20% compared to matching placebo, with fewer serious adverse events (49.6% vs 53.8%) and greater benefit in patients with baseline eGFR <60. PICO Description Population Adults with overweight/obesity (BMI ≥27) and established CVD, without diabetes, from SELECT trial. Intervention Semaglutide 2.4 mg subcutaneously once weekly for median 3.4 years. Comparison Matching placebo weekly for…
Author: FWA
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved NYHA functional class (32.6% improved ≥1 class), with consistent KCCQ and physical function improvements across baseline NYHA categories compared to matching placebo, with similar weight reduction (~8%) regardless of baseline NYHA class and fewer patients experiencing deterioration. PICO Description Population 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%), NYHA class II-IV. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks, titrated per standard protocol. Comparison Matching placebo weekly for 52 weeks, double-blind randomized.…
Summary: In adults with type 2 diabetes and CKD (eGFR 25-75, UACR >100-5000 mg/g) on stable ACEi/ARB therapy, semaglutide 1.0 mg once weekly for median 3.4 years reduced primary composite kidney outcome (kidney failure, ≥50% eGFR decline, kidney/CV death) by 24% (HR 0.76, P<0.001), all-cause mortality by 20%, and CV events by 18% compared to matching placebo, with fewer serious adverse events (49.6% vs 53.8%) and trial stopped early for efficacy. PICO Description Population Adults with T2D and CKD (eGFR 25-75, UACR >100-5000) on stable ACEi/ARB. Intervention Semaglutide 1.0 mg subcutaneous weekly for median 3.4 years. Comparison Matching placebo weekly…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly reduced NT-proBNP, with KCCQ improvements greatest in highest NT-proBNP tertile (up to 11.9 points) compared to matching placebo, with consistent weight loss (~8%) across all NT-proBNP tertiles regardless of cardiac disease severity. PICO Description Population 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%), stratified by NT-proBNP tertiles. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly, double-blind. Outcome NT-proBNP reduced. KCCQ up to +11.9 in highest…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg) for 40 weeks demonstrated significantly greater improvements in beta-cell function (C-peptide, proinsulin) and insulin sensitivity, with superior HbA1c reduction (2.1-2.4% vs 1.9%) and weight loss (11-13 kg vs 9.6 kg) compared to semaglutide 1.0 mg weekly, with consistent benefits regardless of baseline beta-cell function or insulin resistance status. PICO Description Population Adults with T2D (n=1,879) from 128 sites in 8 countries in SURPASS-2 trial. Intervention Tirzepatide 5, 10, or 15 mg subcutaneous weekly for 40 weeks. Comparison Semaglutide 1.0 mg…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40 years), tirzepatide (dual GIP/GLP-1 agonist) for 40-52 weeks achieved comparable improvements in both groups: HbA1c -2.6% vs -2.4%, weight -14 kg vs -13 kg, waist circumference -10 cm, triglycerides -26% vs -24%, SBP -6 vs -7 mmHg compared to later-onset T2D outcomes under identical trial conditions, with robust efficacy regardless of age at diagnosis despite worse baseline metabolic profiles in early-onset patients. PICO Description Population Adults from SURPASS-1, -2, -3 (n=3,792), stratified by early-onset (<40y) vs later-onset (≥40y) T2D. Intervention…
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater liver fat reduction (CAP score), liver enzyme improvements (ALT, AST, GGT), and enhanced glycemic/lipid control compared to monotherapy with either semaglutide alone or empagliflozin alone, with no unexpected adverse signals supporting the combination approach. PICO Description Population Overweight/obese adults with type 2 diabetes and NAFLD. Intervention Combination semaglutide (GLP-1 RA) plus empagliflozin (SGLT2i) for 52 weeks. Comparison Monotherapy with either semaglutide alone or empagliflozin alone for 52 weeks. Outcome Greater liver fat reduction (CAP), improved liver enzymes, enhanced HbA1c and…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved KCCQ-CSS (+7.5 points, P<0.0001), body weight (-8.4%, P<0.0001), 6MWD (+17.1m, P<0.0001), and CRP (-36%, P<0.0001) compared to matching placebo, with fewer serious adverse events (161 vs 301) and consistent benefits regardless of diabetes status. PICO Description Population 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) from pooled trials. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly, double-blind. Outcome KCCQ +7.5, weight -8.4%,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved KCCQ-CSS (+13.7 vs +6.4 points, difference 7.3, P<0.001), weight (-9.8% vs -3.4%), 6MWD, and CRP levels compared to matching placebo, with fewer serious adverse events (17.7% vs 28.8%). PICO Description Population 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. Comparison Matching placebo weekly for 52 weeks. Outcome KCCQ +7.3 difference. Weight -9.8% vs -3.4%. Serious AEs 17.7% vs 28.8%. Clinical Context…
Summary: In adults with long-standing T2D inadequately controlled on current therapy, subcutaneous tirzepatide (dual GIP/GLP-1 agonist) in Phase 1 trial significantly enhanced both first- and second-phase insulin secretion, improved whole-body insulin sensitivity, and enabled normoglycemia achievement compared to semaglutide (selective GLP-1 RA) and placebo, demonstrating mechanistic superiority of dual agonism over selective GLP-1 agonism. PICO Description Population Adults with long-standing T2D inadequately controlled on current therapy. Intervention Tirzepatide (dual GIP/GLP-1 agonist), Phase 1 randomized double-blind trial. Comparison Semaglutide (selective GLP-1 RA) and placebo with metabolic phenotyping. Outcome Enhanced beta-cell function and insulin sensitivity. Normoglycemia achieved in established T2D. Clinical Context…